Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.

This study reported that more sensitive, early diagnosis and treatment of COVID-19 with drug combinations significantly improved clinical outcomes in males with or without androgenetic alopecia, preventing severe progression.

This study observed that males with androgenetic alopecia using dutasteride showed significantly improved COVID-19 outcomes, including shorter duration of symptoms and viral shedding, compared to those not using it and non-AGA males.

In this study, early treatment with nitazoxanide, ivermectin, or hydroxychloroquine, combined with azithromycin, was associated with reduced hospitalizations, respiratory complications, and deaths in early-stage COVID-19 patients compared to untreated controls.

This study observed that early treatment with azithromycin and either nitazoxanide, ivermectin, or hydroxychloroquine in COVID-19 patients may reduce viral shedding, symptom duration, and respiratory complications compared to untreated patients.